In the last trading session, 2.14 million Chromadex Corp (NASDAQ:CDXC) shares changed hands as the company’s beta touched 2.08. With the company’s per share price at $7.25 changed hands at $0.24 or 3.42% during last session, the market valuation stood at $553.78M. CDXC’s last price was a premium, traded about 2.34% off its 52-week high of $7.08. The share price had its 52-week low at $1.32, which suggests the last value was 81.79% up since then. When we look at Chromadex Corp’s average trading volume, we note the 10-day average is 5.22 million shares, with the 3-month average coming to 994.10K.
Analysts gave the Chromadex Corp (CDXC) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.00. If we narrow down to specifics, the data shows that 0 out of 1 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended CDXC as a Hold, 1 felt it is a Buy and 0 rated the stock as Underweight. Chromadex Corp’s EPS for the current quarter is expected to be 0.02.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Chromadex Corp (NASDAQ:CDXC) trade information
Instantly CDXC was in green as seen at the end of in last trading. With action 18.66%, the performance over the past five days has been green. The company’s shares are showing year-to-date upside of 406.99%, with the 5-day performance at 18.66% in the green. However, in the 30-day time frame, Chromadex Corp (NASDAQ:CDXC) is 112.61% up. Looking at the short shares, we see there were 2.96 million shares sold at short interest cover period of 10.17 days.
Chromadex Corp (CDXC) estimates and forecasts
Data shows that the Chromadex Corp share is performing relatively much better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot 98.09% over the past 6 months, a 157.14% in annual growth rate that is considerably higher than the industry average of 17.10%. Year-over-year growth is forecast to reach 16.30% up from the last financial year.
Consensus estimates given by 3 financial analysts project the company’s revenue in the current quarter to hit an average of 26.75M. 3 analysts are of the opinion that Chromadex Corp’s revenue for the current quarter will be 27.59M. The company’s revenue for the corresponding quarters a year ago was 21.2M and 22.15M respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at 26.20%. The estimates for the next quarter sales put growth at 24.50%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 35.83%. The 2024 estimates are for Chromadex Corp earnings to increase by 157.14%.
CDXC Dividends
Chromadex Corp is expected to release its next quarterly earnings report in December.
Chromadex Corp (NASDAQ:CDXC)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 35.39% of Chromadex Corp shares while 22.68% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 35.10%. There are 22.68% institutions holding the Chromadex Corp stock share, with VANGUARD GROUP INC the top institutional holder. As of 2024-06-30, the company held 4.5014% of the shares, roughly 3.39 million CDXC shares worth $9.24 million.
BLACKROCK INC. holds the second largest percentage of outstanding shares, with 4.1422% or 3.12 million shares worth $8.51 million as of 2024-06-30.
